Mr. Speaker, the drug approval regulatory process is in total disarray. On one side of the issue, we have a minister who, on his own signature, can override the best scientific analysis his department can provide to approve a drug knowing full well he always has to err on the side of caution.
On the other side of the issue, we have cancer fighting drugs, life saving drugs that have been bogged down in the regulatory process going on two years. Some of these drugs were approved two years ago in other jurisdictions and in other countries.
How can the minister continue to operate under this conflicting set of guidelines within his own department?